RFX5

Across TCGA pan-cancer cohorts, RFX5 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RFX5 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RFX5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RFX5 expression acts as an unfavorable survival marker.

BRCA, SCLC, and BLCA are the cancer types where RFX5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.106	0.906	<.001	34	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
ESCA	OS	Median	III,IV	0.136	0.573	.023	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
THCA	OS	Median	All	0.342	0.955	<.001	3	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RFX5–BRCA (OS)

Open the BRCA breakdown →